Leflumax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Leflumax

Quick Facts: Leflumax (Levofloxacin)

Property Description
Active Ingredient Levofloxacin
Form Tablets, Sterile Infusion Solution, Ophthalmic Solution
Pharmacological Class Fluoroquinolone Antibiotic
Type Synthetic, Single-Ingredient Product, Prescription-Only (Rx)
General Purpose Bacterial Infection Eradication

Defining Leflumax: A Fluoroquinolone Antibiotic

Leflumax is a prescription-only (Rx), synthetic antimicrobial agent whose core identity is derived from its active ingredient, Levofloxacin. Levofloxacin is classified as a potent, broad-spectrum fluoroquinolone antibiotic and is utilized for its clinically recognized role in managing critical infections. As a quinolone derivative, Levofloxacin is the specific, highly active L-isomer of the related drug Ofloxacin. This chemical refinement contributes to its effectiveness against a wide range of susceptible bacteria, making it a therapeutic choice in cases like serious respiratory or skin infections.

Composition and Available Forms of Levofloxacin

The medicine is a single-ingredient product, containing only Levofloxacin combined with non-active components. To facilitate the appropriate treatment approach, it is manufactured in three primary dosage forms: tablets for oral delivery, a sterile solution for intravenous infusion, and an ophthalmic solution (eye drops). Levofloxacin is used to address infections in several body systems. This flexibility allows for its systemic delivery to treat internal infections, or targeted topical delivery for localized surface infections, such as those of the eye.

The Bactericidal Purpose of Levofloxacin

The essential purpose of Leflumax is to eliminate the causative bacteria, as it functions as a robust bactericidal agent. This means its primary action is designed to actively kill the microorganism rather than simply inhibiting its growth. This mechanism, which targets the bacteria’s essential genetic processes, results in the swift and effective eradication of the microorganism, achieving the general therapeutic goal of resolving bacterial disease.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Leflumax?

The safety profile of Leflumax (Levofloxacin) is strictly documented by government regulatory agencies, outlining potential adverse reactions classified by frequency and affected body system. This profile emphasizes specific serious risks associated with the fluoroquinolone class.

Documented Serious and Disabling Reactions

Official labeling warns of disabling and potentially irreversible serious adverse reactions that may occur together, affecting multiple systems including the musculoskeletal and nervous systems. These include Tendinitis and Tendon Rupture (which may occur as early as 48 hours or months after stopping treatment), Peripheral Neuropathy, and Central Nervous System (CNS) effects (such as anxiety, confusion, and convulsions) that can occur after the first dose.

Other serious risks include potentially fatal reactions such as Severe Hepatotoxicity, Anaphylactic Reactions, Aortic Aneurysm and Dissection, and Prolongation of the QT Interval (risk of Torsade de pointes).

Common Reactions and Risk Groups

Frequency Classification Examples
Most Common (ge 3% incidence) Nausea, Headache, Diarrhea, Insomnia, Dizziness
Organ Systems Affected Gastrointestinal, Nervous System, Musculoskeletal, Cardiac, Immune, Dermatological

Population-Specific Safety: The risk of tendon disorders is officially noted as increased in specific groups, including older patients (typically over 60 years of age), patients with renal impairment, and those with solid organ transplants.

Safety Restrictions

Leflumax is formally contraindicated (must not be used) in patients with a known history of hypersensitivity to any quinolone, a history of tendon disorders related to previous quinolone use, or a history of epilepsy or seizure disorders. Use is also to be avoided in patients with a known history of Myasthenia Gravis due to the risk of exacerbation of muscle weakness.

The regulatory safety summary defines a stringent risk framework centered on the potential for rare but critical adverse reactions across major organ systems, informing the use of this antibiotic.

Overdose and Emergency Response

The official regulatory profile for an acute overdosage of Levofloxacin details specific clinical manifestations and mandates immediate emergency actions.

Documented Manifestations and Severe Outcomes

Category Official Regulatory Description
Central Nervous System (CNS) Manifestations may include dizziness, drowsiness, disorientation, and slurred speech. Convulsions (seizures) are listed as a potential severe outcome.
Cardiovascular System Overdosage is associated with the potential for Prolongation of the QT Interval, a critical cardiac finding. Isolated cases of the life-threatening arrhythmia Torsade de Pointes have been reported.
Gastrointestinal Overdose symptoms include nausea and vomiting.

Mandatory Emergency Response

In the event of suspected overdosage, the regulatory documents mandate that users seek immediate medical attention. It is required to contact a Poison Control Center or the Emergency Room at once.

Management Procedures and Constraints

No specific antidote is known; therefore, treatment is symptomatic and supportive. Management procedures include promoting stomach emptying, such as administering activated charcoal. Due to the cardiac risk, ECG monitoring of the patient is mandatory. Levofloxacin is documented as not efficiently removed by hemodialysis or peritoneal dialysis, meaning these procedures offer little benefit in overdose treatment.

Therapeutic Uses of Leflumax

What Leflumax Treats: Main Uses and Benefits

Leflumax is used for managing a variety of bacterial infections that may affect the lungs, kidneys, and skin.

Leflumax is applied across domains where additional symptomatic support is needed, primarily for conditions characterized by periods of heightened symptoms and significant physiological stress. It is commonly used to help with acute episodes such as community-acquired pneumonia, acute exacerbations of chronic bronchitis, complicated urinary tract infections (cUTIs), acute pyelonephritis, and complicated skin and soft tissue infections. For specific high-risk scenarios, it is also relevant in contexts involving management following exposure to pathogens like inhalational anthrax.

The medication is relevant for easing symptoms related to inflammatory states, such as high fever, persistent cough, chest discomfort, severe pain, and burning during urination. Treatment with this medication may help provide support related to addressing the bacterial cause, which assists with maintaining functional stability.

“Its role is focused on providing supportive relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Acute Discomfort

Symptom Axis Condition Category Primary Benefit
Systemic Discomfort (e.g., fever, chills) Conditions with heightened systemic burden Supports general well-being during symptomatic phases
Organ-Specific Strain (e.g., dysuria, flank pain) Conditions where functional stability is affected Assists with maintaining functional stability
Physical Strain (e.g., cough, chest pain) Conditions presenting with disruptive manifestations Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

Leflumax (Levofloxacin) is a prescription-only antibiotic whose official eligibility profile strictly defines which populations are approved for use and which are excluded or restricted, based on regulatory documentation.

Formal Contraindicated Populations

The medicine must not be used in the following groups, as established by governmental health authorities:

  • Patients with known hypersensitivity or allergy to Levofloxacin or any other quinolone antibiotic.
  • Individuals with a history of epilepsy or certain tendon disorders related to previous fluoroquinolone treatment.
  • Children and growing adolescents for general systemic indications (use is restricted to specific, life-threatening infections, such as anthrax, in patients ge 6 months of age).
  • Women who are pregnant or breastfeeding.

Eligibility-Related Restrictions

Use is often conditional or requires special consideration in specific populations:

  • Renal Impairment: Patients with reduced kidney function (e.g., severe renal impairment) require a mandatory dose adjustment to prevent the drug from accumulating in the body.
  • Older Adults (ge 65 years): Although use is permitted, caution is advised due to increased documented risks, including a higher risk of tendon injury.
  • Comorbidities: Use is restricted or advised against in patients with Myasthenia Gravis (risk of exacerbation) or those with existing risk factors for QT interval prolongation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Leflumax (levofloxacin) documents several clinically significant interactions with other medicinal products and non-drug substances.

Interactions Affecting Leflumax Exposure (Chelation):

The absorption of Leflumax is significantly reduced when co-administered with products containing multivalent cations, which form chelates. This includes antacids, sucralfate, didanosine formulations with buffering agents, and mineral supplements containing iron, zinc, or magnesium. This reduced absorption can lower drug effectiveness. To manage this interaction, specific timing requirements are necessary for oral administration, such as separating the Leflumax dose from the interacting agent by at least two hours.

Interactions Affecting Co-administered Drug Exposure:

Leflumax may affect other medications. When combined with Vitamin K antagonists (e.g., Warfarin), there is a risk of increased coagulation tests (Prothrombin Time/INR) and bleeding, necessitating close monitoring of the patient’s coagulation status. Exposure to Ciclosporin may also be increased when co-administered.

Pharmacodynamic Interaction Risks:

Regulatory documents identify additive safety risks. Co-administration with corticosteroids increases the risk of tendinitis and tendon rupture, an established constraint for use. Concomitant use with drugs that prolong the QT interval (e.g., Class IA and III antiarrhythmics, certain tricyclic antidepressants) is noted as a cautious use scenario due to the additive risk of heart rhythm changes. Furthermore, concurrent use with non-steroidal anti-inflammatory drugs (NSAIDs) or theophylline may lower the cerebral seizure threshold.

Mechanism of Action

Leflumax is an antibiotic that functions as a highly specific enzyme inhibitor, primarily targeting core processes within susceptible bacterial cells.

The mechanism is centered on two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. Leflumax binds to the DNA-enzyme complexes, preventing the necessary cutting and resealing actions required for bacterial DNA unwinding and separation. This interaction stabilizes temporary breaks in the DNA strands, leading to permanent, irreparable double-strand damage. This molecular cascade induces the rapid and lethal consequence of bacterial cell death. The mechanism is classified as bactericidal and results in the inactivation of susceptible microbial populations via direct cellular disruption, producing a consequential reduction in the number of targeted microorganisms.

Dosage and Administration Information

How to Use Leflumax

The usage of Leflumax (Levofloxacin) is strictly governed by protocols outlined in official documents, defining the administration, frequency, and duration of the medication. The medicine is available in three distinct forms: oral tablets, a sterile solution for intravenous (IV) infusion, and an ophthalmic solution for topical application.


Official Administration and Dosing

Systemic dosing, whether oral or intravenous, follows a standard Once Daily (QD) frequency. The specific dose amount ranges from 250 mg to 750 mg, which is linked directly to the required treatment duration.

Administration Route Standard Adult Dose Range Typical Frequency
Oral/IV Systemic 250 mg to 750 mg Once Daily (QD)
Topical Ophthalmic 0.5% or 1.5% strength Titrated Schedule

Procedural Context and Adjustments

Oral administration offers flexibility as it may be taken with or without food; however, it must be separated by at least two hours from products containing metal cations (e.g., antacids or iron supplements). When administered intravenously, the solution requires a slow infusion rate, specifically at least 60 to 90 minutes, depending on the dose delivered.

For patients with impaired kidney function (Creatinine Clearance less than 50 mL/min), a mandatory dose adjustment is required to modify the amount and/or the interval between doses. Treatment duration is predefined and can range from a short 3-day course for specific infections to a long 60-day course for certain prophylactic regimens. These official instructions define the standardized, non-advisory structure for the appropriate use of Levofloxacin.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Leflumax

This summary provides an overview of the types of research conducted for Leflumax (Levofloxacin), outlining what outcomes were measured and where gaps in the evidence exist. This information is based on controlled studies and scientific reviews. Research does not determine whether an individual will respond similarly.


Evidence for Community-Acquired Pneumonia and Acute Respiratory Infections

Research into Leflumax was studied for managing Community-Acquired Pneumonia (CAP) and acute exacerbations of Chronic Bronchitis (ABECB) primarily involves controlled studies and systematic reviews. In these research scenarios, investigators were often exploring short-term symptom changes. Studies monitored key endpoints, including the Clinical Efficacy Rate (which tracked the change in acute symptoms) and the Microbiological Eradication Rate (which monitored the presence of causative bacteria). For severe forms of pneumonia, studies have also monitored outcomes related to functional imbalance, such as Time to Clinical Stability and the rate of all-cause mortality over defined time intervals.


Evidence for Complicated Urinary Tract and Skin Infections

Leflumax was studied for Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (a kidney infection) in controlled trials. These studies were conducted during periods of increased symptom activity and focused on outcomes linked to inflammatory or irritative states, such as the complete resolution of symptoms like fever and flank pain. Studies monitored both the Clinical Cure Rate and the Microbiological Eradication Rate at a specific follow-up appointment. Data show patterns related to bacterial clearance observed in the studies. Research provides context but not individual predictions; the monitoring of antibiotic resistance in the bacteria causing these conditions is a subject of ongoing study.


What Remains Uncertain in the Research Landscape

The overall body of evidence highlights what is known—and what is still uncertain. For Inhalational Anthrax, research relies on a surrogate endpoint and animal data, meaning direct human efficacy data is unavailable. For many common indications, follow-up durations were limited to the immediate post-treatment period; there is limited information for long-term outcomes or functional status. Furthermore, data for certain groups, such as those with specific comorbidities or the most severe infections requiring ICU admission, are often derived from smaller observational studies, meaning subgroup findings are uncertain and not as robust as the main trial data.

Frequently Asked Questions (FAQ)

Common questions about Leflumax (FAQ)

Q: What is the main reason a doctor might prescribe Leflumax?

Official documents define the medicine's purpose as treating a wide range of bacterial infections. Regulatory agencies have indicated the medicine for specific conditions, including specific types of pneumonia, complicated urinary tract infections, and skin and soft tissue infections caused by susceptible bacteria.

Q: How quickly can someone expect Leflumax to start working?

Clinical studies supporting the drug's use measure outcomes such as the 'Clinical Efficacy Rate' and 'Time to Clinical Stability.' These measures track the time it takes for a patient to progress toward clinical stability. However, official information also notes that the time it takes for an individual patient to feel better can vary.

Q: Does Leflumax interact with common over-the-counter pain relievers?

Official documents note that caution is advised when taking this medicine with non-steroidal anti-inflammatory drugs (NSAIDs) because of a potential risk of lowering the seizure threshold in the brain. The official product information does not list a specific interaction with Acetaminophen (Paracetamol).

Q: Can taking Leflumax make someone feel tired or sleepy?

The official safety profile commonly lists nervous system side effects such as dizziness and insomnia (trouble sleeping). Some regulatory summaries also note that fatigue or tiredness is a documented adverse reaction.

Q: Can people with liver problems take Leflumax?

Official product information states that no adjustment of the dose is required for patients with pre-existing impaired liver function. This is because the medicine is primarily processed by the kidneys, not the liver. However, a rare but serious risk of severe liver damage (Hepatotoxicity) is officially noted for all patients.

Q: What is known about the long-term safety profile of Leflumax?

Regulatory documents indicate that clinical studies supporting the medicine's use often have limited follow-up duration. For most common indications, long-term safety information is limited for durations of therapy beyond 28 days.

Q: Why is it important to have regular blood tests while taking Leflumax?

Official labeling states that blood cell counts should be monitored during treatment. Furthermore, if the medicine is taken alongside Vitamin K antagonists (like Warfarin), monitoring of blood coagulation tests is necessary due to an increased risk of bleeding.

Q: Does Leflumax cause skin rashes or increased sensitivity to the sun?

Regulatory warnings advise that the medicine may cause photosensitivity, which is an increased sensitivity to the sun. This can result in an exaggerated sunburn reaction. The official warning advises avoiding exposure to strong sunlight or artificial UV light while using the medication.

Q: Is it necessary to avoid driving or operating machinery while on Leflumax (non-directive)?

Caution is advised in official product information regarding driving or operating heavy machinery. This is because the medicine can cause nervous system effects like dizziness, headache, or other Central Nervous System (CNS) disturbances that may impair a person's ability to concentrate.

Q: Are there known allergic reactions to the non-active ingredients in Leflumax?

Official documents state that the medicine is formally contraindicated in patients with a known hypersensitivity not only to the active substance (Levofloxacin) or any other quinolone, but also to any of the excipients (non-active ingredients) used in the product formulation.

Q: Do regulatory warnings mention any specific lifestyle changes needed while taking Leflumax?

Regulatory documents contain specific warnings regarding exposure to sunlight or artificial UV light due to the risk of photosensitivity. Additionally, official guidance requires separation of oral doses from products containing metal cations, such as iron supplements or antacids, by at least two hours.

Q: Is it normal to feel no difference immediately after starting Leflumax?

The medicine is designed to be taken for a duration ranging from a few days to several weeks, and clinical studies measure the full effect over this period. Since the onset of action is not immediate, official information suggests that a patient may not feel a subjective change immediately after starting the medication.

Q: Is Leflumax used to prevent symptoms or only to manage them?

Official regulatory documents confirm that the medicine is approved for both the treatment of established infections and for specific prophylactic regimens (preventative use). For example, it is used for post-exposure prophylaxis for certain conditions, which can involve a longer, 60-day course.

Q: What happens if I forget to take a dose of Leflumax?

Official patient information leaflets include specific procedural guidance for managing a missed dose. This guidance outlines the protocol for taking a forgotten dose if remembered soon after, or for skipping the forgotten dose if it is close to the next scheduled administration. The guidance always advises against taking a double dose.

Q: Does Leflumax need to be tapered off, or can I stop taking it suddenly?

Regulatory guidance emphasizes that the full prescribed course of therapy must be completed to effectively treat the infection. Official documents do not include specific instructions for 'tapering off' the medicine.

Q: Has the FDA (or similar regulatory body) approved Leflumax for all its mentioned uses?

Regulatory agencies, such as the FDA, publish a specific list of Therapeutic Indications (approved uses) for which the medicine has been formally tested and deemed safe and effective. These approved uses are the only ones described in official documentation.

Q: What should be done if an interaction with another drug is suspected?

Official patient counseling information describes the procedure to follow if a drug interaction or any severe adverse reaction is suspected. This procedure includes stopping the use of the medicine and immediately contacting a healthcare provider or an emergency physician.

Q: Is there a generic version of Leflumax available?

The active ingredient in Leflumax is Levofloxacin. Following the expiration of the original patent protection, the active ingredient is available from various manufacturers as a generic medicine.

Q: Are there any known interactions between Leflumax and herbal supplements?

Official regulatory warnings focus on interactions with prescription medicines and products containing multivalent cations (e.g., iron, zinc, or magnesium), which can be found in some vitamins and supplements. Patient leaflets generally include a recommendation to inform the prescribing healthcare professional about all supplements, including herbal ones.

Q: Where can I find the official patient information leaflet for Leflumax?

The official Patient Information Leaflet (PIL) or Patient Labeling can be found on government-run authority websites. Agencies such as the EMA, MHRA, or the FDA's DailyMed publish these documents as part of their drug authorization and monitoring.

Q: Is Leflumax known to interact with birth control pills?

Official drug interaction data generally does not list a specific, clinically significant interaction between this medicine and hormonal birth control pills.

Q: What are the potential risks for someone who accidentally takes too much Leflumax?

Regulatory documents state that symptoms following an overdose may involve the nervous system. These documented signs include confusion, dizziness, impaired consciousness, convulsions, and changes to the heart rhythm known as prolongation of the QT interval.

How should Leflumax be stored and disposed of?

How to Store and Dispose of Leflumax?

Official regulatory documents define strict rules for the storage and disposal of Leflumax (Levofloxacin) tablets, focusing on maintaining stability and ensuring public safety.

Required Storage Conditions

Leflumax must be stored at controlled room temperature, generally defined as 25 C (77 F), with permitted temperature excursions up to 30 C (86 F). To protect the product's integrity, it is mandatory to store the medicine in its original, tightly closed container to shield it from light and moisture.

Storage Axis Official Requirement
Temperature Do not store above 30 C
Protection Keep in original container; protect from light and moisture
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Leflumax must be disposed of according to local, national, or international regulations for pharmaceutical waste. Disposal instructions prohibit emptying the medicine into drains, water courses, or onto the ground to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Leflumax found in:

A-Z Index: